New diabetes clinical trial: Seltoplasmid Plus Revascularization for Diabetic Infrapopliteal Chronic Limb-Threatening Ischemia
Published on: 2026-09-18T04:00:00Z
Conditions: Chronic Limb-Threatening Ischemia; Diabetic Foot Ulcer; Infrapopliteal Arterial Occlusive Disease
Interventions: Procedure: Lower-Extremity Revascularization; Genetic: Donaperminogene Seltoplasmid
Sponsors: First Affiliated Hospital of Wenzhou Medical University; Beijing Northland Biotech. Co., Ltd.
Not yet recruiting
https://ift.tt/cJMeNCO
Conditions: Chronic Limb-Threatening Ischemia; Diabetic Foot Ulcer; Infrapopliteal Arterial Occlusive Disease
Interventions: Procedure: Lower-Extremity Revascularization; Genetic: Donaperminogene Seltoplasmid
Sponsors: First Affiliated Hospital of Wenzhou Medical University; Beijing Northland Biotech. Co., Ltd.
Not yet recruiting
https://ift.tt/cJMeNCO
Comments
Post a Comment